Insider Transactions in Q1 2023 at Alkermes Plc. (ALKS)
Insider Transaction List (Q1 2023)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 22
2023
|
Michael J Landine SVP, Corp Dev., Alkermes, Inc. |
SELL
Payment of exercise price or tax liability
|
Direct |
2,462
-0.97%
|
$66,474
$27.77 P/Share
|
|
Feb 22
2023
|
Michael J Landine SVP, Corp Dev., Alkermes, Inc. |
BUY
Exercise of conversion of derivative security
|
Direct |
5,544
+2.15%
|
-
|
|
Feb 22
2023
|
Christian Todd Nichols SVP, Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,704
-5.28%
|
$73,008
$27.77 P/Share
|
|
Feb 22
2023
|
Christian Todd Nichols SVP, Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,969
+11.98%
|
-
|
|
Feb 22
2023
|
Iain Michael Brown SVP, Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,049
-2.41%
|
$55,323
$27.77 P/Share
|
|
Feb 22
2023
|
Iain Michael Brown SVP, Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,969
+7.59%
|
-
|
|
Feb 22
2023
|
David Joseph Gaffin EVP, CLO, Alkermes, Inc. |
SELL
Payment of exercise price or tax liability
|
Direct |
3,224
-2.48%
|
$87,048
$27.77 P/Share
|
|
Feb 22
2023
|
David Joseph Gaffin EVP, CLO, Alkermes, Inc. |
BUY
Exercise of conversion of derivative security
|
Direct |
7,286
+5.3%
|
-
|
|
Feb 22
2023
|
Craig C. Hopkinson EVP R&D, Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,345
-8.63%
|
$144,315
$27.77 P/Share
|
|
Feb 22
2023
|
Craig C. Hopkinson EVP R&D, Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
12,038
+16.28%
|
-
|
|
Feb 22
2023
|
Blair Curtis Jackson EVP, Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,088
-2.63%
|
$83,376
$27.77 P/Share
|
|
Feb 22
2023
|
Blair Curtis Jackson EVP, Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
9,504
+7.5%
|
-
|
|
Feb 21
2023
|
Richard F Pops Director and CEO, Alkermes plc |
SELL
Payment of exercise price or tax liability
|
Direct |
14,386
-1.35%
|
$388,422
$27.77 P/Share
|
|
Feb 21
2023
|
Richard F Pops Director and CEO, Alkermes plc |
BUY
Exercise of conversion of derivative security
|
Direct |
32,400
+2.95%
|
-
|
|
Feb 21
2023
|
David Joseph Gaffin EVP, CLO, Alkermes, Inc. |
SELL
Payment of exercise price or tax liability
|
Direct |
2,022
-1.62%
|
$54,594
$27.77 P/Share
|
|
Feb 21
2023
|
David Joseph Gaffin EVP, CLO, Alkermes, Inc. |
BUY
Exercise of conversion of derivative security
|
Direct |
6,875
+5.22%
|
-
|
|
Feb 21
2023
|
Blair Curtis Jackson EVP, Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,412
-1.29%
|
$38,124
$27.77 P/Share
|
|
Feb 21
2023
|
Blair Curtis Jackson EVP, Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,800
+4.21%
|
-
|
|
Feb 21
2023
|
Michael J Landine SVP, Corp Dev., Alkermes, Inc. |
SELL
Payment of exercise price or tax liability
|
Direct |
2,587
-1.04%
|
$69,849
$27.77 P/Share
|
|
Feb 21
2023
|
Michael J Landine SVP, Corp Dev., Alkermes, Inc. |
BUY
Exercise of conversion of derivative security
|
Direct |
5,825
+2.28%
|
-
|
|
Feb 21
2023
|
Iain Michael Brown SVP, Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
1,412
-1.78%
|
$38,124
$27.77 P/Share
|
|
Feb 21
2023
|
Iain Michael Brown SVP, Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,800
+5.71%
|
-
|
|
Feb 21
2023
|
Craig C. Hopkinson EVP R&D, Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
3,053
-5.77%
|
$82,431
$27.77 P/Share
|
|
Feb 21
2023
|
Craig C. Hopkinson EVP R&D, Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
6,875
+11.5%
|
-
|
|
Feb 20
2023
|
Richard F Pops Director and CEO, Alkermes plc |
SELL
Payment of exercise price or tax liability
|
Direct |
53,145
-4.88%
|
$1,488,060
$28.07 P/Share
|
|
Feb 20
2023
|
Richard F Pops Director and CEO, Alkermes plc |
BUY
Grant, award, or other acquisition
|
Direct |
119,713
+9.91%
|
-
|
|
Feb 20
2023
|
David Joseph Gaffin EVP, CLO, Alkermes, Inc. |
SELL
Payment of exercise price or tax liability
|
Direct |
6,617
-2.8%
|
$185,276
$28.07 P/Share
|
|
Feb 20
2023
|
David Joseph Gaffin EVP, CLO, Alkermes, Inc. |
BUY
Grant, award, or other acquisition
|
Direct |
15,468
+11.21%
|
-
|
|
Feb 20
2023
|
David Joseph Gaffin EVP, CLO, Alkermes, Inc. |
BUY
Exercise of conversion of derivative security
|
Direct |
7,036
+6.06%
|
-
|
|
Feb 20
2023
|
Blair Curtis Jackson EVP, Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,316
-2.07%
|
$120,848
$28.07 P/Share
|
|
Feb 20
2023
|
Blair Curtis Jackson EVP, Chief Operating Officer |
BUY
Grant, award, or other acquisition
|
Direct |
10,086
+8.59%
|
-
|
|
Feb 20
2023
|
Blair Curtis Jackson EVP, Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,589
+4.45%
|
-
|
|
Feb 20
2023
|
Michael J Landine SVP, Corp Dev., Alkermes, Inc. |
SELL
Payment of exercise price or tax liability
|
Direct |
7,604
-1.54%
|
$212,912
$28.07 P/Share
|
|
Feb 20
2023
|
Michael J Landine SVP, Corp Dev., Alkermes, Inc. |
BUY
Grant, award, or other acquisition
|
Direct |
11,770
+4.51%
|
-
|
|
Feb 20
2023
|
Michael J Landine SVP, Corp Dev., Alkermes, Inc. |
BUY
Exercise of conversion of derivative security
|
Direct |
5,354
+2.18%
|
-
|
|
Feb 20
2023
|
Christian Todd Nichols SVP, Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
7,878
-8.56%
|
$220,584
$28.07 P/Share
|
|
Feb 20
2023
|
Christian Todd Nichols SVP, Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
22,969
+31.06%
|
-
|
|
Feb 20
2023
|
Christian Todd Nichols SVP, Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,824
+11.6%
|
-
|
|
Feb 20
2023
|
Iain Michael Brown SVP, Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,316
-2.9%
|
$120,848
$28.07 P/Share
|
|
Feb 20
2023
|
Iain Michael Brown SVP, Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
10,086
+11.52%
|
-
|
|
Feb 20
2023
|
Iain Michael Brown SVP, Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
4,589
+6.26%
|
-
|
|
Feb 20
2023
|
Craig C. Hopkinson EVP R&D, Chief Medical Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
10,306
-11.74%
|
$288,568
$28.07 P/Share
|
|
Feb 20
2023
|
Craig C. Hopkinson EVP R&D, Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
22,195
+29.69%
|
-
|
|
Feb 20
2023
|
Craig C. Hopkinson EVP R&D, Chief Medical Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
10,095
+22.81%
|
-
|
|
Feb 18
2023
|
David Joseph Gaffin EVP, CLO, Alkermes, Inc. |
SELL
Payment of exercise price or tax liability
|
Direct |
1,945
-1.87%
|
$54,460
$28.07 P/Share
|
|
Feb 18
2023
|
David Joseph Gaffin EVP, CLO, Alkermes, Inc. |
BUY
Exercise of conversion of derivative security
|
Direct |
6,230
+5.65%
|
-
|
|
Feb 18
2023
|
Blair Curtis Jackson EVP, Chief Operating Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
2,683
-2.78%
|
$75,124
$28.07 P/Share
|
|
Feb 18
2023
|
Blair Curtis Jackson EVP, Chief Operating Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
8,722
+8.28%
|
-
|
|
Feb 18
2023
|
Michael J Landine SVP, Corp Dev., Alkermes, Inc. |
SELL
Payment of exercise price or tax liability
|
Direct |
2,065
-0.87%
|
$57,820
$28.07 P/Share
|
|
Feb 18
2023
|
Michael J Landine SVP, Corp Dev., Alkermes, Inc. |
BUY
Exercise of conversion of derivative security
|
Direct |
4,361
+1.81%
|
-
|